GTHX · Categories · Form 4

GTHX - SEC Form 4 insider transactions

G1 Therapeutics Inc. (GTHX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for GTHX

• 623d
  Chief Legal & People Officer Thomas Monica R. returned 138,151 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Flowers Cynthia Louise returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Secor Alicia returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Chief Financial Officer Umstead John W. V returned 168,387 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Chief Operating Officer Murdock Terry L was granted 17,900 shares and returned 124,762 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Lee Jacks returned 10,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  President and CEO Bailey John E. (Jack) Jr. was granted 181,400 shares and returned 534,787 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Nicholson Garry A returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Chief Business Officer Avagliano Mark was granted 20,600 shares and returned 236,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Chief Medical Officer Malik Rajesh was granted 17,900 shares and returned 89,762 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Chief Commercial Officer Perry Andrew was granted 16,100 shares and returned 114,482 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Sharpless Norman returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 623d
  Director Muir Glenn P returned 20,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  Chief Commercial Officer Perry Andrew sold $3,353 worth of shares (1,337 units at $2.51), decreasing direct ownership by 1% to 112,614 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  Chief Operating Officer Murdock Terry L sold $6,207 worth of shares (2,475 units at $2.51), decreasing direct ownership by 2% to 128,012 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  Chief Medical Officer Malik Rajesh sold $6,207 worth of shares (2,475 units at $2.51), decreasing direct ownership by 2% to 159,312 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  Chief Business Officer Avagliano Mark sold $6,615 worth of shares (2,638 units at $2.51), decreasing direct ownership by 1% to 242,045 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  Chief Financial Officer Umstead John W. V sold $1,322 worth of shares (527 units at $2.51), decreasing direct ownership by 0.28% to 187,718 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 695d
  President and CEO Bailey John E. (Jack) Jr. sold $19,214 worth of shares (7,662 units at $2.51), decreasing direct ownership by 1% to 549,674 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  Chief Commercial Officer Perry Andrew was granted 35,000 shares, increasing direct ownership by 44% to 113,951 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  Chief Operating Officer Murdock Terry L was granted 35,000 shares, increasing direct ownership by 37% to 130,487 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  Chief Legal & People Officer Thomas Monica R. was granted 35,000 shares, increasing direct ownership by 32% to 144,825 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  Chief Business Officer Avagliano Mark was granted 35,000 shares, increasing direct ownership by 17% to 244,683 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  Chief Financial Officer Umstead John W. V was granted 35,000 shares, increasing direct ownership by 23% to 188,245 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 700d
  President and CEO Bailey John E. (Jack) Jr. was granted 105,000 shares, increasing direct ownership by 23% to 557,336 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Sharpless Norman was granted 10,000 shares, increasing direct ownership by 100% to 20,000 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Secor Alicia was granted 10,000 shares, increasing direct ownership by 50% to 30,000 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Muir Glenn P was granted 10,000 shares, increasing direct ownership by 5% to 205,358 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Lee Jacks was granted 10,000 shares, increasing direct ownership by 100% to 20,000 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Flowers Cynthia Louise was granted 10,000 shares, increasing direct ownership by 39% to 35,889 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 719d
  Director Nicholson Garry A was granted 10,000 shares, increasing direct ownership by 41% to 34,389 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 740d
  Thomas Monica R. sold $24,864 worth of shares (5,826 units at $4.27), decreasing direct ownership by 5% to 109,825 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 749d
  Murdock Terry L sold $39,034 worth of shares (8,151 units at $4.79), decreasing direct ownership by 8% to 95,487 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 749d
  Umstead John W. V sold $39,034 worth of shares (8,151 units at $4.79), decreasing direct ownership by 5% to 153,245 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 749d
  Malik Rajesh sold $39,034 worth of shares (8,151 units at $4.79), decreasing direct ownership by 5% to 161,787 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 749d
  Avagliano Mark sold $39,034 worth of shares (8,151 units at $4.79), decreasing direct ownership by 4% to 209,683 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 749d
  Bailey John E. (Jack) Jr. sold $178,421 worth of shares (37,258 units at $4.79), decreasing direct ownership by 8% to 452,336 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 803d
  Thomas Monica R. was granted 37,500 shares, increasing direct ownership by 48% to 115,651 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 803d
  Avagliano Mark was granted 100,000 shares, increasing direct ownership by 85% to 217,834 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 803d
  Umstead John W. V was granted 37,500 shares, increasing direct ownership by 30% to 161,396 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 805d
  Umstead John W. V sold $19,752 worth of shares (6,547 units at $3.02), decreasing direct ownership by 5% to 123,896 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 841d
  Malik Rajesh exercised 28,600 shares at a strike of $0.30 and sold $132,143 worth of shares (28,600 units at $4.62) (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Umstead John W. V sold $2,298 worth of shares (743 units at $3.09) and was granted 37,300 shares, increasing direct ownership by 39% to 130,443 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Thomas Monica R. was granted 27,975 shares, increasing direct ownership by 56% to 78,151 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Malik Rajesh was granted 37,300 shares and sold $11,537 worth of shares (3,740 units at $3.08), increasing direct ownership by 25% to 169,938 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Perry Andrew was granted 33,570 shares and sold $7,526 worth of shares (2,413 units at $3.12), increasing direct ownership by 56% to 87,102 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Bailey John E. (Jack) Jr. was granted 100,700 shares and sold $36,447 worth of shares (11,686 units at $3.12), increasing direct ownership by 22% to 489,594 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Avagliano Mark was granted 44,760 shares and sold $12,601 worth of shares (4,081 units at $3.09), increasing direct ownership by 53% to 117,834 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 877d
  Murdock Terry L was granted 37,300 shares and sold $11,537 worth of shares (3,740 units at $3.08), increasing direct ownership by 48% to 103,638 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 883d
  Bailey John E. (Jack) Jr. sold $108,006 worth of shares (32,983 units at $3.27), decreasing direct ownership by 8% to 400,580 units (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 903d
  Malik Rajesh exercised 33,839 shares at a strike of $0.36 and sold $115,522 worth of shares (33,839 units at $3.41) (SEC Form 4)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1028d
  SEC Form 4: Velleca Mark A. exercised 60,000 shares at a strike of $0.39 and sold $119,974 worth of shares (60,000 units at $2.00)

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1062d
  SEC Form 4 filed by Murdock Terry L

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1062d
  SEC Form 4 filed by Bailey John E. (Jack) Jr.

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1062d
  SEC Form 4 filed by Perry Andrew

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1062d
  SEC Form 4 filed by Malik Rajesh

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1083d
  SEC Form 4 filed by Sharpless Norman

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1083d
  SEC Form 4 filed by Muir Glenn P

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1083d
  SEC Form 4 filed by Flowers Cynthia Louise

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
• 1083d
  SEC Form 4 filed by Lee Jacks

  4 - G1 Therapeutics, Inc. (0001560241) (Issuer)

Other GTHX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends